Regado to present REG1 Phase 2b trial results against acute coronary syndromes at i2 Summit

Mar 29 2011

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that Thomas J. Povsic, MD, PhD, Assistant Professor of Medicine at Duke University, will present results of the RADAR Phase 2b clinical trial for the Company's lead product, the REG1 anticoagulation system, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo.

The presentation, "A Randomized, Partially-Blinded, Multi-Center, Active-Controlled, Dose-ranging Study Assessing the Safety, Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Weight Heparin in Subjects with Acute Coronary Syndromes: Primary Results of the RADAR Randomized Clinical Trial," will be given during an i2 Special Session entitled: "Interventional Featured Clinical Studies I" on Sunday, April 3, 2011 at 1:15 p.m. CDT at the Ernest N. Morial Convention Center in New Orleans, LA.

REG1 comprises a two-component system; a highly selective Factor IXa inhibiting aptamer, pegnivacogin, and its complementary specific active control agent, anivamersen.  Anivamersen can be used to selectively reverse (completely or partially) the anticoagulant effect of pegnivacogin in real time.

SOURCE Regado Biosciences, Inc.